New York Luna Care Physical Therapy Pllc | |
1 Blue Hill Plz Ste 1509, Pearl River, NY 10965-3165 | |
(877) 839-6979 | |
Not Available |
Full Name | New York Luna Care Physical Therapy Pllc |
---|---|
Type | Facility |
Speciality | Physical Therapist |
Location | 1 Blue Hill Plz Ste 1509, Pearl River, New York |
Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194314062 | NPI | - | NPPES |
Provider Name | Richard Augeri |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1033283973 PECOS PAC ID: 7012990369 Enrollment ID: I20040609000499 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Robert Mccabe |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1831112796 PECOS PAC ID: 8123007762 Enrollment ID: I20040716000440 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Liza Tan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1982628764 PECOS PAC ID: 3779542303 Enrollment ID: I20041007000747 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Melody Bautista |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1548368962 PECOS PAC ID: 4880651801 Enrollment ID: I20041215000010 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nova Ginete Gil |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407113996 PECOS PAC ID: 3971542689 Enrollment ID: I20050502000466 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Denis C Marais |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1790736015 PECOS PAC ID: 3870504210 Enrollment ID: I20060519000132 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Korina Gahol Galaraga |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1114014974 PECOS PAC ID: 1557360310 Enrollment ID: I20061206000062 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Gregory P Taylor |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1689774119 PECOS PAC ID: 3375543267 Enrollment ID: I20061227000090 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Robert V Dilorenzo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1982629911 PECOS PAC ID: 8628172186 Enrollment ID: I20070323000042 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Dmitry Lang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1457486334 PECOS PAC ID: 8426155623 Enrollment ID: I20070523000406 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Rhona Mason-fogah |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1669519583 PECOS PAC ID: 3779675772 Enrollment ID: I20070822001030 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Karen Hillman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1649304288 PECOS PAC ID: 7517054141 Enrollment ID: I20071030000283 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Shari A Rosen |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1770535379 PECOS PAC ID: 5597834325 Enrollment ID: I20080520000685 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | John Wilbert |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1538117874 PECOS PAC ID: 7214007509 Enrollment ID: I20080529000216 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Theresa Marko |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1588638753 PECOS PAC ID: 5395754733 Enrollment ID: I20080619000403 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sherry E Bender |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1811137987 PECOS PAC ID: 0042367724 Enrollment ID: I20090415000513 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brian M Moynihan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023192705 PECOS PAC ID: 9931251071 Enrollment ID: I20090721000133 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher Wong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316270580 PECOS PAC ID: 5294873493 Enrollment ID: I20091109000427 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Teresa A Parziale |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1417197278 PECOS PAC ID: 1456499565 Enrollment ID: I20091110000740 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Rubina D Casaol |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1114235074 PECOS PAC ID: 1254529936 Enrollment ID: I20101222000146 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicholas Por |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1629026026 PECOS PAC ID: 8426247180 Enrollment ID: I20110111000563 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Samson K Olojede |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1598818569 PECOS PAC ID: 0547432528 Enrollment ID: I20111018000018 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Farrah R Sharkey Goring |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1518189802 PECOS PAC ID: 3375718646 Enrollment ID: I20111215000007 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Eun Jung Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1467712620 PECOS PAC ID: 6103082078 Enrollment ID: I20120720000258 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Gary Sarmiento Abano |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1679866016 PECOS PAC ID: 6406002211 Enrollment ID: I20120810000195 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sherrie N Jasper |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1578837647 PECOS PAC ID: 6002063898 Enrollment ID: I20120830000120 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Page A Baker |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1699073577 PECOS PAC ID: 6800036633 Enrollment ID: I20130628000053 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kristine Mae R Uday-cadiz |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245483957 PECOS PAC ID: 4183867492 Enrollment ID: I20130905000093 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Latika M Thakur |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1821360678 PECOS PAC ID: 6103075627 Enrollment ID: I20131203000133 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Morlay Kamara |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316207467 PECOS PAC ID: 3274760871 Enrollment ID: I20131205000265 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Michelle Maria De Guzman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1063816536 PECOS PAC ID: 5496077604 Enrollment ID: I20141125000838 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Stephanie Weinstein |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1467859389 PECOS PAC ID: 9739402686 Enrollment ID: I20141229000880 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Andy Zhu |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1457745010 PECOS PAC ID: 7315265345 Enrollment ID: I20150423000226 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Shari Goodhart |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1528477486 PECOS PAC ID: 8729308564 Enrollment ID: I20150519002461 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Patrick Joseph Crangle |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1518342898 PECOS PAC ID: 7315255569 Enrollment ID: I20151007002922 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jaemin Park |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1699144352 PECOS PAC ID: 5890095822 Enrollment ID: I20151124001611 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | James Falesto |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1356745053 PECOS PAC ID: 4082915848 Enrollment ID: I20151221000928 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Annie M Neisen |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1477951622 PECOS PAC ID: 4789985557 Enrollment ID: I20151221001351 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ogechi Nwaneri |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1235503640 PECOS PAC ID: 2961704002 Enrollment ID: I20160107000279 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jordan P Seda |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1730561044 PECOS PAC ID: 2860791365 Enrollment ID: I20160505000343 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jairo Abreu |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1467698191 PECOS PAC ID: 9638468176 Enrollment ID: I20160523001293 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Samson Chacko |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1730432527 PECOS PAC ID: 6901192962 Enrollment ID: I20160831001548 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jonathan Kim |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1801341573 PECOS PAC ID: 7113214669 Enrollment ID: I20160927001120 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Samantha Hernandez |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336694728 PECOS PAC ID: 0749577229 Enrollment ID: I20160927002008 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jason Cooper |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1346674249 PECOS PAC ID: 0941437487 Enrollment ID: I20161017002015 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ryan Mckeough |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1871979716 PECOS PAC ID: 1456649888 Enrollment ID: I20161018000338 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ariel Osharenko |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1609258847 PECOS PAC ID: 0547566028 Enrollment ID: I20161108002294 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Matthew Burns |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407225766 PECOS PAC ID: 8729367016 Enrollment ID: I20161109000066 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Boris Avezov |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336690361 PECOS PAC ID: 0547540783 Enrollment ID: I20161206001196 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Vanessa Volmar-virobyan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1235673674 PECOS PAC ID: 1456632991 Enrollment ID: I20161221001631 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Samuel Franco |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861935934 PECOS PAC ID: 1658653837 Enrollment ID: I20170124000284 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sijo Thomas |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1508301151 PECOS PAC ID: 3476836156 Enrollment ID: I20170202001672 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sonrisa Aparece |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1609167725 PECOS PAC ID: 6406130228 Enrollment ID: I20170222002921 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Yael Hecht |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1629514088 PECOS PAC ID: 6103100177 Enrollment ID: I20170313000683 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Marian Princess S Cerisier |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1144751389 PECOS PAC ID: 1355627787 Enrollment ID: I20170419000159 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jonathan Isaac Noury |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1699215269 PECOS PAC ID: 6608152061 Enrollment ID: I20170419001589 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Omar Elgendy |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1205368719 PECOS PAC ID: 7517244502 Enrollment ID: I20170428001490 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Flavia Lopes Soares |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1780944975 PECOS PAC ID: 1658658448 Enrollment ID: I20170504000003 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Akshita Shetty |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1912426396 PECOS PAC ID: 7113292442 Enrollment ID: I20171012000410 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Stephen Lobiondo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1922511138 PECOS PAC ID: 0840557971 Enrollment ID: I20171128002628 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Seokcheon Ham |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1851787642 PECOS PAC ID: 4486967288 Enrollment ID: I20180130000365 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Salvattore L L Portocarrero |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1164938155 PECOS PAC ID: 6507127123 Enrollment ID: I20180222002096 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hyunjeong Jang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1982104071 PECOS PAC ID: 1850654302 Enrollment ID: I20180413001914 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Thalia Aquino Neis |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1164727939 PECOS PAC ID: 8325302193 Enrollment ID: I20180502000770 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Eleanor Innocent |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1003144155 PECOS PAC ID: 0547524076 Enrollment ID: I20180508002330 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brando Lydell Lakes |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1801386503 PECOS PAC ID: 3072869445 Enrollment ID: I20180628000239 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kiwon Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1528545324 PECOS PAC ID: 7012265879 Enrollment ID: I20180810000214 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Neri M Villaluna |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1770772600 PECOS PAC ID: 1658629399 Enrollment ID: I20180813000746 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Demetrios Michel |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1689153405 PECOS PAC ID: 6709136419 Enrollment ID: I20180830000113 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alexandra Kahn |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1912489717 PECOS PAC ID: 8921359845 Enrollment ID: I20180914002391 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alvin So |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1558845438 PECOS PAC ID: 3577815398 Enrollment ID: I20181005001550 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jonathan Louis Rodriguez |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1215419593 PECOS PAC ID: 2961756424 Enrollment ID: I20181120000262 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Gary Heller |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1659846277 PECOS PAC ID: 6305183724 Enrollment ID: I20190123002780 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Eunjung Choi |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1528598745 PECOS PAC ID: 1951648955 Enrollment ID: I20190129003254 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Dominique Rowe |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1255802773 PECOS PAC ID: 0143568543 Enrollment ID: I20190211000694 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Daniel Vallejo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1275007478 PECOS PAC ID: 8527306885 Enrollment ID: I20190212000267 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Eunhyeong Kim |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1689130767 PECOS PAC ID: 5193064871 Enrollment ID: I20190225000040 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Somer Meyers |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861967416 PECOS PAC ID: 2769721232 Enrollment ID: I20190227001703 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Rommel S Santos |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1376071746 PECOS PAC ID: 9335489046 Enrollment ID: I20190315001675 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Erica Moore |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1043776339 PECOS PAC ID: 0446591457 Enrollment ID: I20190401000270 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mcbernard Gregorio |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1548729973 PECOS PAC ID: 7315288156 Enrollment ID: I20190404001823 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brian Feng |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1487211751 PECOS PAC ID: 3072846187 Enrollment ID: I20190605000091 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Bonghak Ji |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1144887597 PECOS PAC ID: 9032442025 Enrollment ID: I20190606000406 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jaeyoung Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1396238523 PECOS PAC ID: 6507192523 Enrollment ID: I20190812002471 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Tyler Scott Rosenberg |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1194371898 PECOS PAC ID: 8426386749 Enrollment ID: I20190826000072 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Emma Jane Codman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1457911026 PECOS PAC ID: 5991034829 Enrollment ID: I20190903000305 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mackenzie Battaglini Pert |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1922656974 PECOS PAC ID: 0446589972 Enrollment ID: I20190910000313 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Victoria Stambolian |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1740838739 PECOS PAC ID: 4486983921 Enrollment ID: I20190910000659 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Emily Phillips |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1235787433 PECOS PAC ID: 9133458326 Enrollment ID: I20190913000551 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jisu Yu |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316594831 PECOS PAC ID: 5799015442 Enrollment ID: I20190924001499 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Wen Hao Wang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1144870700 PECOS PAC ID: 5991035321 Enrollment ID: I20190926002282 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Karl Roderic Bynes |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1851606438 PECOS PAC ID: 0941530208 Enrollment ID: I20190930001522 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Maciej Skala |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1417373234 PECOS PAC ID: 4183955883 Enrollment ID: I20191010002062 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sweta Singh |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1588215727 PECOS PAC ID: 7517298870 Enrollment ID: I20191017001504 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Baron Shieh |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1811539638 PECOS PAC ID: 5698006955 Enrollment ID: I20191017001577 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Shevvie Sialana |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1568009116 PECOS PAC ID: 3779916663 Enrollment ID: I20191206002021 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alan Wong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1427695097 PECOS PAC ID: 2163855917 Enrollment ID: I20191209001466 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicholas J Silletti |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1487122727 PECOS PAC ID: 2860737335 Enrollment ID: I20191213001846 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Michael Sansone |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1487290391 PECOS PAC ID: 8820421373 Enrollment ID: I20191213001937 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jenny Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1821637182 PECOS PAC ID: 0345674917 Enrollment ID: I20200107003280 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Czarissa Espanol Casalme |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336788421 PECOS PAC ID: 7315372786 Enrollment ID: I20200113000454 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Iancu Capusan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861039620 PECOS PAC ID: 3779918131 Enrollment ID: I20200114001183 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hoiman Poon |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1326696444 PECOS PAC ID: 8224463484 Enrollment ID: I20200115002769 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Zhi Jing Huang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1053956789 PECOS PAC ID: 7618302498 Enrollment ID: I20200124001994 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Carl Christian Mangurali Suico |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1275170557 PECOS PAC ID: 1052747359 Enrollment ID: I20200205001084 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Maica Tuazon Padios |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1740747955 PECOS PAC ID: 7810323011 Enrollment ID: I20200206002539 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher Repecki |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023670221 PECOS PAC ID: 8022445535 Enrollment ID: I20200224000081 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Philip Chan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1992345227 PECOS PAC ID: 8628405974 Enrollment ID: I20200226000096 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Maged Abuseif |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1487128898 PECOS PAC ID: 4587091640 Enrollment ID: I20200302001520 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | May-wen Jillian Lye |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1881150910 PECOS PAC ID: 8628406303 Enrollment ID: I20200311000715 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jheng-kai Shih |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1851926208 PECOS PAC ID: 9931520582 Enrollment ID: I20200607000000 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Amr H Mostafa |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1003369505 PECOS PAC ID: 2668896382 Enrollment ID: I20200728001150 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Soojung Jung |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1518583103 PECOS PAC ID: 2062837719 Enrollment ID: I20200729001341 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Tessia Correa De Mattos |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023627460 PECOS PAC ID: 2365867256 Enrollment ID: I20200810001999 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Anthony Lombardo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1730799545 PECOS PAC ID: 8921424995 Enrollment ID: I20200820002996 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Allison Zheng |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1760090898 PECOS PAC ID: 2961829635 Enrollment ID: I20200826000783 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Irene Pauline Padilla Ilagan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1417569377 PECOS PAC ID: 4880012806 Enrollment ID: I20200908002112 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Meera Rao |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407486582 PECOS PAC ID: 3779901657 Enrollment ID: I20200909000727 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mohamed Abohussein Abohussein |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1144834474 PECOS PAC ID: 8426476847 Enrollment ID: I20200917001021 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Karl Matthew Custodio Josol |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1720693492 PECOS PAC ID: 0547689275 Enrollment ID: I20200930001469 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hesham A Ahmed |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1467068510 PECOS PAC ID: 4789004813 Enrollment ID: I20201012001516 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jean Qi |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1053924712 PECOS PAC ID: 1951721448 Enrollment ID: I20201022001043 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Qiqi Zhong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1477169365 PECOS PAC ID: 2567882053 Enrollment ID: I20201022001200 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kara Louelle Casino |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1811505720 PECOS PAC ID: 8820418288 Enrollment ID: I20201023001357 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mandar Patel |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1801406350 PECOS PAC ID: 3971913377 Enrollment ID: I20201112002375 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Seongjae Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437779329 PECOS PAC ID: 5991116428 Enrollment ID: I20201204000562 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Francesco Chiodi |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1912513524 PECOS PAC ID: 6103237656 Enrollment ID: I20201204001383 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alexandra Siegrist |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1922607027 PECOS PAC ID: 3577975317 Enrollment ID: I20201218001697 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hamdi Darouich |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1700486362 PECOS PAC ID: 0749693422 Enrollment ID: I20210120000505 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ivan Rafael Villar Rivera |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1447882428 PECOS PAC ID: 6901211937 Enrollment ID: I20210224001568 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Junsuk Oh |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1225638679 PECOS PAC ID: 4688080120 Enrollment ID: I20210309001340 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Eli Lamberson |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1366938458 PECOS PAC ID: 9234488297 Enrollment ID: I20210310001182 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Martine Szanto |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437736378 PECOS PAC ID: 2769899251 Enrollment ID: I20210330000370 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Young Sook Choi |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1295951358 PECOS PAC ID: 8729495098 Enrollment ID: I20210402000678 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Gail Paguntalan Ocampo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861910028 PECOS PAC ID: 2466860465 Enrollment ID: I20210412001407 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicholas P Fanelli |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316527088 PECOS PAC ID: 6204244817 Enrollment ID: I20210421000015 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sheung Wei Li |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1982289898 PECOS PAC ID: 3274941505 Enrollment ID: I20210426001347 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Youngki Kong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1134768005 PECOS PAC ID: 3375951619 Enrollment ID: I20210504000568 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hung-yen Lin |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1366087975 PECOS PAC ID: 8921417338 Enrollment ID: I20210513002948 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Fatimah U Dawan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1710165295 PECOS PAC ID: 5991104481 Enrollment ID: I20210603002398 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Majhi Marie Jumawid Villahermosa |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1760824080 PECOS PAC ID: 9335548783 Enrollment ID: I20210604001405 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Marcus Dubouzet |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1588238422 PECOS PAC ID: 8022417484 Enrollment ID: I20210604001575 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hina Javed |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1174007009 PECOS PAC ID: 5294135695 Enrollment ID: I20210607000908 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jessica Gutierrez |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1770162133 PECOS PAC ID: 6204236979 Enrollment ID: I20210617000481 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Temitope Seun Akinlade |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1326617093 PECOS PAC ID: 6204237761 Enrollment ID: I20210622002762 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicole Lombardo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1750837886 PECOS PAC ID: 5991083487 Enrollment ID: I20210629000151 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Suhan Woo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1588201578 PECOS PAC ID: 9739580549 Enrollment ID: I20210630004171 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Arielle Klig |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1386984235 PECOS PAC ID: 1052712791 Enrollment ID: I20210701001223 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jahong Koo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861031627 PECOS PAC ID: 1951704972 Enrollment ID: I20210728000629 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Rose Anne Mae Salazar Luzuriaga |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1508437146 PECOS PAC ID: 7911301478 Enrollment ID: I20210804004196 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Michael Kypros |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1992344477 PECOS PAC ID: 2961822739 Enrollment ID: I20210806001795 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Deshaunda Borrel |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1184227415 PECOS PAC ID: 5092119313 Enrollment ID: I20210810000185 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ranan N Hui |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1295409555 PECOS PAC ID: 9830593094 Enrollment ID: I20210810001907 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kenneth Bing |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1902444805 PECOS PAC ID: 3072918283 Enrollment ID: I20210826001841 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Timothy Dontel Brown |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1457029217 PECOS PAC ID: 0840696274 Enrollment ID: I20210909001691 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Karen Skolnik |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316263908 PECOS PAC ID: 3173920295 Enrollment ID: I20210916000500 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Shannon Garrity |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245710003 PECOS PAC ID: 3678970480 Enrollment ID: I20210921003268 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Zihao Du |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1952989386 PECOS PAC ID: 4183021470 Enrollment ID: I20210929002813 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Vince Rian T. Padios |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1770255655 PECOS PAC ID: 4789082801 Enrollment ID: I20211004002959 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Masemantha Monique Molina |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1053945881 PECOS PAC ID: 5193142099 Enrollment ID: I20211005001239 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ishmael Nausrudeen |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1700559762 PECOS PAC ID: 7810395571 Enrollment ID: I20211011000463 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kevin W Freeman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437751971 PECOS PAC ID: 7618375346 Enrollment ID: I20211012000133 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Micah Tobia |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1932789609 PECOS PAC ID: 4688072101 Enrollment ID: I20211013001095 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Denzel Cherry |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1235656299 PECOS PAC ID: 7517209133 Enrollment ID: I20211015001921 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Daniel Batteiger |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861155012 PECOS PAC ID: 7113315458 Enrollment ID: I20211019002396 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sara Foxman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336814623 PECOS PAC ID: 7214325497 Enrollment ID: I20211020000995 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Justin Baharally |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1275296949 PECOS PAC ID: 6002204138 Enrollment ID: I20211022000882 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jacky Chow |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1043985872 PECOS PAC ID: 2567850563 Enrollment ID: I20211025001255 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sean Doyle |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407478993 PECOS PAC ID: 8022406727 Enrollment ID: I20211029001318 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Matthew Elliott |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1487003141 PECOS PAC ID: 7719278605 Enrollment ID: I20211102001079 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Cally Chang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1639748114 PECOS PAC ID: 0547658999 Enrollment ID: I20211104000164 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Darshiv Atul Nayak |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1346850419 PECOS PAC ID: 5395134647 Enrollment ID: I20211108002724 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Adam Cagliuso |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1508257171 PECOS PAC ID: 5294124418 Enrollment ID: I20211109003307 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Errin Jean Donahue |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1376213033 PECOS PAC ID: 0941699953 Enrollment ID: I20211112001750 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Menatalla Mahmoud |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1871180448 PECOS PAC ID: 4981093671 Enrollment ID: I20211118002035 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher J. Wojton |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407124555 PECOS PAC ID: 1355730946 Enrollment ID: I20211122000540 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Salvador Lara |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861791428 PECOS PAC ID: 0749670982 Enrollment ID: I20211202002072 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Andre Benzer |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1659039220 PECOS PAC ID: 4284024233 Enrollment ID: I20211206001565 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Pauravi P Shroff |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1871621698 PECOS PAC ID: 1658761283 Enrollment ID: I20211214000518 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Marcus Reis |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1073117164 PECOS PAC ID: 0244621712 Enrollment ID: I20211217001222 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nardeen Abdelsayed |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1508522210 PECOS PAC ID: 7618368853 Enrollment ID: I20211227000325 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ivan Enerio |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1639739089 PECOS PAC ID: 1456742550 Enrollment ID: I20211228001878 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Darla L Mitu |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336756774 PECOS PAC ID: 0446641435 Enrollment ID: I20211230000907 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Zeyad Elamrousy |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1114698024 PECOS PAC ID: 6305238056 Enrollment ID: I20220110001356 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Joshua Anthony B Suapengco |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1154080596 PECOS PAC ID: 4183016454 Enrollment ID: I20220118001560 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brianna Michaels |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1447919600 PECOS PAC ID: 6507258498 Enrollment ID: I20220127000357 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mark Samaan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1205304227 PECOS PAC ID: 0941693840 Enrollment ID: I20220216001449 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ma Agnes Rivera |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1942954847 PECOS PAC ID: 6608260393 Enrollment ID: I20220223000096 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Shreya Wadhawan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1831762657 PECOS PAC ID: 9234532003 Enrollment ID: I20220310002779 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sanghyun Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1699361808 PECOS PAC ID: 9537554472 Enrollment ID: I20220311001430 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Andy Seraphin |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1326658485 PECOS PAC ID: 1254757594 Enrollment ID: I20220317002105 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Laura Manfredo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1598314783 PECOS PAC ID: 5395131296 Enrollment ID: I20220401000233 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher Falciano |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1902441140 PECOS PAC ID: 9234525775 Enrollment ID: I20220408000994 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Pruettiyapa Manosan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1396309910 PECOS PAC ID: 6901296276 Enrollment ID: I20220411000070 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Katerina Parlamas |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1124769294 PECOS PAC ID: 4486040839 Enrollment ID: I20220412000415 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Joey Chan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1346837721 PECOS PAC ID: 3971999111 Enrollment ID: I20220415000253 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brandon Woo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1447905864 PECOS PAC ID: 4789070939 Enrollment ID: I20220415000639 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Min Ji Kang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1780353656 PECOS PAC ID: 8426435710 Enrollment ID: I20220505001959 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Natalia Pelaez |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245975523 PECOS PAC ID: 6608253729 Enrollment ID: I20220511001372 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sam Wang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1174097737 PECOS PAC ID: 6901283043 Enrollment ID: I20220511002047 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Frederick Huang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407592801 PECOS PAC ID: 7911384995 Enrollment ID: I20220512000946 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sukhdeep Singh |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1013657709 PECOS PAC ID: 3678950664 Enrollment ID: I20220512001666 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sentia Weche |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336441252 PECOS PAC ID: 4789061607 Enrollment ID: I20220516001350 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Audrey Mccarthy |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1336883461 PECOS PAC ID: 1951788710 Enrollment ID: I20220517000392 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Yoonhee Cho |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1740852722 PECOS PAC ID: 1355728080 Enrollment ID: I20220518000149 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Namjune Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1841838984 PECOS PAC ID: 0042698011 Enrollment ID: I20220602002405 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Colleen Stitt |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861098006 PECOS PAC ID: 9032597752 Enrollment ID: I20220608000351 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Martel Perry |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1669122453 PECOS PAC ID: 8123406691 Enrollment ID: I20220613001035 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Otto Lam |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1558995480 PECOS PAC ID: 4284013780 Enrollment ID: I20220613002945 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hyunju Yoo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1184262727 PECOS PAC ID: 7113306622 Enrollment ID: I20220614000069 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Darren Joffe |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1225787054 PECOS PAC ID: 9436538741 Enrollment ID: I20220616001498 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Swikriti Pokhrel |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1184355232 PECOS PAC ID: 2668852229 Enrollment ID: I20220629002233 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jinyoung Kim |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1083379416 PECOS PAC ID: 0840670386 Enrollment ID: I20220630001331 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Malik Ahmed Ali |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1275270563 PECOS PAC ID: 0345620381 Enrollment ID: I20220707002635 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Abbey Roberts |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1013677376 PECOS PAC ID: 3577944214 Enrollment ID: I20220713000775 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | David Meyer |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407190648 PECOS PAC ID: 1951651462 Enrollment ID: I20220715001378 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Damian Johnson |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245960418 PECOS PAC ID: 0446631725 Enrollment ID: I20220718002360 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hyosuk Kim |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1922753839 PECOS PAC ID: 1658752993 Enrollment ID: I20220719000918 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Dahyun Heo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1376277830 PECOS PAC ID: 5294117016 Enrollment ID: I20220726002952 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | April Silvestre |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1225333453 PECOS PAC ID: 4385026244 Enrollment ID: I20220809002437 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Giorlan Sososco Olvido |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1376278234 PECOS PAC ID: 2668854555 Enrollment ID: I20220809003650 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicouhl Jay Tolentino Rivera |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1639755895 PECOS PAC ID: 3971986019 Enrollment ID: I20220823000090 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jerome T Rivera |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023670361 PECOS PAC ID: 3577946524 Enrollment ID: I20220824000573 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ernest Stukes |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1962001800 PECOS PAC ID: 0345624862 Enrollment ID: I20220901002563 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nikita Meswani |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023580354 PECOS PAC ID: 6406262450 Enrollment ID: I20220913000380 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Koji Okamoto |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1043485592 PECOS PAC ID: 2860653029 Enrollment ID: I20220926002093 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Reyson Baldomir |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1447845516 PECOS PAC ID: 1153707096 Enrollment ID: I20220930000249 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jane Elizabeth Weedon |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1124252853 PECOS PAC ID: 4486030012 Enrollment ID: I20221004003427 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Katherine Elifritz |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1346873577 PECOS PAC ID: 1951739358 Enrollment ID: I20221006002069 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Danny Kwok |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437871332 PECOS PAC ID: 2365828795 Enrollment ID: I20221007001136 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Michael Mecner |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1972221448 PECOS PAC ID: 2264818517 Enrollment ID: I20221010003225 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Irene Kafkis |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1477213734 PECOS PAC ID: 0345616611 Enrollment ID: I20221012002094 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Deanna Madagan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1962125641 PECOS PAC ID: 2062888175 Enrollment ID: I20221014000684 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sijia Zhang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1275294266 PECOS PAC ID: 0941676720 Enrollment ID: I20221019001677 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Keith Tan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1871217513 PECOS PAC ID: 6002282779 Enrollment ID: I20221020001869 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mario Politis |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1760154595 PECOS PAC ID: 8527435817 Enrollment ID: I20221028001602 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Neiladri Kumar Mallick |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1871217984 PECOS PAC ID: 8527435783 Enrollment ID: I20221101002914 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Charles Adedara |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1184085235 PECOS PAC ID: 3274953971 Enrollment ID: I20221108000254 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alana Roytvarf |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1104437730 PECOS PAC ID: 3375962913 Enrollment ID: I20221109001050 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Heewon Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1790372621 PECOS PAC ID: 0345618245 Enrollment ID: I20221128001387 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Marylene Pineda |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1154964856 PECOS PAC ID: 9335517168 Enrollment ID: I20221128002717 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Diether Paul O Quintana |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1518550342 PECOS PAC ID: 3870961659 Enrollment ID: I20221129001864 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher Kirby |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1841914611 PECOS PAC ID: 3678942166 Enrollment ID: I20221205002259 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Madison Anne Pessel |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437810082 PECOS PAC ID: 8022487461 Enrollment ID: I20221207001683 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ingu Lee |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1508450917 PECOS PAC ID: 9830568377 Enrollment ID: I20221216002605 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kevin Chen |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1558933796 PECOS PAC ID: 4688044670 Enrollment ID: I20230109001998 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ahmed Sherief |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1609587104 PECOS PAC ID: 0244600237 Enrollment ID: I20230109002328 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Gabriel Uriel Escalona Palisoc |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1760987309 PECOS PAC ID: 4486024304 Enrollment ID: I20230110001040 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ken Erbvin Rint Sosa |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1639889215 PECOS PAC ID: 5496126260 Enrollment ID: I20230116000170 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jeffrey Sabatini |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1306515572 PECOS PAC ID: 2961809231 Enrollment ID: I20230117000761 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Andrew L Kaplan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245907518 PECOS PAC ID: 0941606495 Enrollment ID: I20230120001673 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Allison Win |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1497406573 PECOS PAC ID: 0345611315 Enrollment ID: I20230131000126 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Philip M Cagliostro |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1720413032 PECOS PAC ID: 4587036199 Enrollment ID: I20230208001034 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Tiffany Mclean |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1235554494 PECOS PAC ID: 4183935604 Enrollment ID: I20230208002434 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jose Antonio Rojas |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1861890568 PECOS PAC ID: 7618349143 Enrollment ID: I20230210000226 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Mae Doll Rana |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1407561921 PECOS PAC ID: 5193197101 Enrollment ID: I20230220002134 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Maryann Katrina Magno Ocampo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1548973340 PECOS PAC ID: 3678946274 Enrollment ID: I20230301002488 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ana Samantha Santos Antonio |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1023724770 PECOS PAC ID: 2365815800 Enrollment ID: I20230302001844 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Efosa Erhunmwunse |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1083312623 PECOS PAC ID: 6103299565 Enrollment ID: I20230306000932 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Joanna Kathrina Repollo Paca |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1518670686 PECOS PAC ID: 8628441953 Enrollment ID: I20230307000713 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Denzel Williams |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1316647613 PECOS PAC ID: 3375917305 Enrollment ID: I20230314003177 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Yeonhwa Jeong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1689177479 PECOS PAC ID: 5092189738 Enrollment ID: I20230321002083 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nieves Jane Osano Espinosa |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1881330454 PECOS PAC ID: 4284008764 Enrollment ID: I20230323002693 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Daniel Vapne |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1114562170 PECOS PAC ID: 5395132435 Enrollment ID: I20230328001871 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Carly Arbeit |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1689241093 PECOS PAC ID: 3072918697 Enrollment ID: I20230403000982 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Sujin Kang |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1841931342 PECOS PAC ID: 2961867619 Enrollment ID: I20230502001190 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Brandon Ong |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1598400368 PECOS PAC ID: 6608232087 Enrollment ID: I20230510002664 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hyun Kyung Jung |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245847953 PECOS PAC ID: 0749646123 Enrollment ID: I20230510002837 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Ching Lam Ko |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1922691112 PECOS PAC ID: 3971969064 Enrollment ID: I20230516000601 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Timothy Waanders |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1558933085 PECOS PAC ID: 5698132975 Enrollment ID: I20230531002992 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hong Gu Yeo |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1902464498 PECOS PAC ID: 2961869011 Enrollment ID: I20230605001188 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Alexandra Murray |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1457035305 PECOS PAC ID: 6204294309 Enrollment ID: I20230622000525 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kent Russell Tiv Siady |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1265068407 PECOS PAC ID: 6406216126 Enrollment ID: I20230713000787 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Simar Ahluwalia |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1649958380 PECOS PAC ID: 5890156277 Enrollment ID: I20230801004040 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Greg Alan Rothman |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1437617446 PECOS PAC ID: 7113388323 Enrollment ID: I20230804000398 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Angelique Esver |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1760162424 PECOS PAC ID: 2567824303 Enrollment ID: I20230810004165 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Christopher P Ju |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1669191482 PECOS PAC ID: 4587033733 Enrollment ID: I20230814000832 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Renee Cleek |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1558645275 PECOS PAC ID: 0143494815 Enrollment ID: I20230814002323 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jose Vince Ambion |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1679284434 PECOS PAC ID: 4688036908 Enrollment ID: I20230817001680 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Nicole Iris Antiligando Gamban |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1962028761 PECOS PAC ID: 9335594001 Enrollment ID: I20231016002506 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Kathleen Soliven Vargas |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1083340459 PECOS PAC ID: 9739536194 Enrollment ID: I20231107003900 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Hyejin Cho |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1386214302 PECOS PAC ID: 6406203462 Enrollment ID: I20231113002249 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Joyce Valerie Balisbis Co |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1851069736 PECOS PAC ID: 5698124428 Enrollment ID: I20231205003901 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Stephen Tran |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1821663345 PECOS PAC ID: 4880043579 Enrollment ID: I20231206002415 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Muftiah Jokomba |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1790367399 PECOS PAC ID: 3072962059 Enrollment ID: I20231215002742 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jelene Nique |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1952022121 PECOS PAC ID: 7214389402 Enrollment ID: I20240124000503 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Lauren Villalva |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1083484471 PECOS PAC ID: 9931552197 Enrollment ID: I20240124003161 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Victor Jomel Militar |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1104446079 PECOS PAC ID: 4789037623 Enrollment ID: I20240127000022 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Naomi Trimble |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1245094408 PECOS PAC ID: 6204270929 Enrollment ID: I20240221000482 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Danielle Daymude |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1033974555 PECOS PAC ID: 0244675122 Enrollment ID: I20240301000995 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Jessica Polizzi |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1285419242 PECOS PAC ID: 3870939911 Enrollment ID: I20240311003414 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Provider Name | Julianne Melissa Khan |
---|---|
Provider Type | Practitioner - Physical Therapist In Private Practice |
Provider Identifiers | NPI Number: 1568689677 PECOS PAC ID: 2769828557 Enrollment ID: I20240315000232 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
New York Luna Care Physical Therapy Pllc Po Box 2350, Rocklin, CA 95677-8350 Ph: (866) 806-3599 | New York Luna Care Physical Therapy Pllc 1 Blue Hill Plz Ste 1509, Pearl River, NY 10965-3165 Ph: (877) 839-6979 |
News Archive
Advocat Inc. today announced that five of its long term care facilities were recognized with 2010 National Quality Awards by the American Healthcare Association (AHCA).
In the largest clinical trial of its kind, researchers show that combining sound and electrical stimulation of the tongue can significantly reduce tinnitus, commonly described as "ringing in the ears." They also found that therapeutic effects can be sustained for up to 12 months post-treatment.
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
One of the roadblocks to the eradication of tuberculosis (TB) is the difficulty in identifying patients with latent TB infections (LTBI). Neither the tuberculin skin test (TST) nor interferon-gamma release assays (IGRAs) are capable of distinguishing active from latent infection or predicting the chance of reactivation.
› Verified 5 days ago
Danielle Daymude, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1 Blue Hill Plz Ste 1509, Pearl River, NY 10965 Phone: 866-839-6979 | |
Ms. Kathleen Soliven Vargas, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1 Blue Hill Plaza, Suite 1509, Pearl River, NY 10965 Phone: 877-839-6979 | |
Lauren Villalva, PT, DPT, GCS Physical Therapist Medicare: Medicare Enrolled Practice Location: 1 Blue Hill Plz Ste 1509, Pearl River, NY 10965 Phone: 866-839-6979 | |
Marielle Lucille Dineen-carey, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Blue Hill Plz Ste 1509, Pearl River, NY 10965 Phone: 866-839-6979 | |
Katerina Parlamas, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1 Blue Hill Plz Ste 1509, Pearl River, NY 10965 Phone: 866-839-6979 | |
Allison Tarsnane, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 75 Bocket Rd, Pearl River, NY 10965 Phone: 917-816-2566 | |
Michele M Gomez, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 401 N Middletown Rd, Pearl River, NY 10965 Phone: 973-851-1221 |